Dr David Hung has joined T-Therapeutics as Chairman of its Board of Directors. In this video, which accompanied the announcement, Dr Hung explains his decision: “I have always wanted to be on the cutting-edge of science and transform the practice of medicine. I...
Read More
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces...
Read More
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines...
Read More